Clinical trial NCT05760092: The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.
Official title: The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19. A Randomized Controlled Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Xerostomia
COVID-19
Long COVID
Persistent COVID-19
Keywords: Xerostomia
Dry Mouth
COVID-19
Long Covid
Photobiomodulation
Lead sponsor: University of Nove de Julho
Sponsor class: OTHER
First posted: 2023-03-08
Enrollment: 10
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) as a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2). Long COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that persists after the acute infection has resolved. The most frequent symptoms of Lonf-term COVID are fatigue and dyspnea. But two classes of symptoms have been received scientific attention: the musculoskeletal pain and oral complaints related to Long COVID, mainly xerostomia and burning mouth. Photobiomodulation (PBM) therapy is often used for oral diseases and presents itself as a non-invasive, low-cost, safe therapy that has benefits in relation to the quality of life of patients with xerostomia. This study aims to investigate the clinical effectiveness of the use of a Photobiomodulation protocol in the treatment xerostomia and oral complaints related to Long-Covid. This will be a single-center, randomized, controlled, blinded clinical trial that will involve patients with Long COVID in follow-up at the Medical and Multiprofessional outpatient clinic of University Nove de Julho (UNINOVE) which remained hospitalized with COVID-19 at Lydia Storópoli Universitarian Hospital during the year 2022 and who were discharged from the inpatient treatment from January to December 2022. All those patients presenting xerostomia, burning mouth or oral complaints related to Long Covid will be randomized into 2 groups: PBM Group (standard rehabilitation treatment for Long COVID and xerostomia + PBM therapy) or PBM placebo group (standard rehabilitation treatment for Long COVID and xerostomia + placebo PBM therapy). PBM consists of the application of Red LED on the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks. Functional and quality of life evaluations will be perform pre and post therapy period.

Detailed description: Coronavirus (COVID-19) is a newly emerging zoonotic agent that emerged in December 2019 in China (2019-nCoV) and which results in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV -2) The scientific literature has made progress in the characterization of the new coronavirus and works extensively on therapies and vaccines against the virus. However, it is now known that SARS-CoV-2 is more than just an acute respiratory syndrome. Long-term COVID-19, or Post-Covid Syndrome or Long-term COVID-19, is a post-viral syndrome that was first reported online in groups of COVID-19 survivors discussing their symptoms after the acute infection has resolved. It begins to gain recognition in the scientific and medical communities. Although a universally accepted definition does not yet exist, reviews have identified that the most frequent symptoms of Lonf-term COVID are fatigue and dyspnea. But two classes of symptoms have been received scientific attention: the musculoskeletal pain and xerostomia. Xerostomia is defined as a subjective sensation of dry mouth described by patients and which is commonly related to hyposalivation (decreased salivary flow rate). The pathophysiology and clinical evolution of xerostomia in COVID-19 still lacks studies, but there are reports of 2 to 30% of patients presenting the complaint of dry mouth sensation even after the resolution of acute COVID. Regular physical therapy, cognitive behavioral therapy have been used and encouraged in the follow-up of patients with post- COVID, demonstrating that even today these practices seem to be more promising than pharmacological treatment. In parallel, studies demonstrate that Photobiomodulation (PBM) therapy is often used for oral diseases and presents itself as a non-invasive, low-cost, safe therapy that has benefits in relation to the quality of life of these patients. PBM refers to a series of therapies in which non-ionizing light beams, including lasers, LEDs and broadband light in the visible and infrared spectra, are used to interact with biological tissues for different purposes. In this sense, this study aims to investigate the clinical effectiveness of the use of a Photobiomodulation protocol in the treatment xerostomia related to Long-Covid. This will be a single-center, randomized, controlled, blind clinical trial that will involve patients with Long-COVID in follow-up at the Medical and Multiprofessional outpatient clinic of University Nove de Julho (UNINOVE). An analysis will be carried out of all medical records of patients who remained hospitalized with COVID-19 at Lydia Storópoli Universitary Hospital during the year 2022 and who were discharged from the inpatient treatment from January to December 2022, for a survey of telephone contact and epidemiological data collection by medical records. All those patients who answer the questions referring to one or more symptoms related to the oral or nasal cavity, which have arisen after the onset of acute COVID infection, will be invited to participate in the study by making a first face-to-face evaluation at the University to confirm the diagnostic criteria of xerostomia, the diagnosis of Long COVID and evaluation of inclusion criteria in the study (adults with COVID-19 with complaints of xerostomia diagnosed more than 4 weeks after the acute infection and persisting for at least 02 months). Pre- and post-treatment evaluations are composed by the Brazilian Version of the SF 36 Quality of Life Scale, salivary sialometry and salivary pH, Oral Health Impact Profile (OHIP-14), Abbreviated Xerostomia Inventory (SXI), Brazilian version of the Functional Independence Measure (FIM), Post -Covid-19 Functional Status Scale and WHO Disability Assessment Scale (WHODAS 2.0) All patients included will be randomized into 2 groups: PBM Group (standard rehabilitation treatment for Long COVID and xerostomia + PBM therapy) or PBM placebo group (standard rehabilitation treatment for Long COVID and xerostomia + placebo PBM therapy). PBM consists of the application of Red LED on the 3 pairs of major salivary glands (parotid, submandibular and sublingual) extraorally, transcutaneously, 3 J/cm2, for 36 seconds, twice a week for 06 weeks. The results will be sent for statistical analysis.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis xerostomia related to Long-COVID;
* more than 4 weeks after the acute infection hat have persisted for at least 02 months (regardless of whether these patients are already using treatment for the complaints or not);
* Age greater than 18 years.

Exclusion Criteria:

* Clinical diagnosis of other previous rheumatological or musculoskeletal diseases that presents xerostomia;
* Previous use in the last 90 days of laser treatment or other photobiomodulation technique for the same or another indication;
* Clinical manifestations or complaints of xerostomia related to diseases other than Long COVID;
* Previous diseases of the oral or nasal cavity that occur with the symptom of xerostomia;
* Systemic inflammatory diseases (rheumatoid arthritis, Reiter's arthritis, ankylosing spondylitis, generalized polyarthritis, neoplasms);
* Uncontrolled metabolic or endocrine diseases;
* Neoplastic diseases;
* Serious cognitive or psychiatric disorders that that do not allow the understanding of the study;
* Steroid injections during the last 48 hours prior to baseline study assessment;
* Use of corticosteroids at an immunosuppressive dose (20mg daily of prednisone or equivalent for at least 14 days);
* Infection or tumor at the site of therapy application;
* Current chronic infections such as tuberculosis or chronic hepatitis treated or not;
* Severe blood dyscrasia;
* Blood clotting disorders (including thrombosis) at the application site;
* Psychoaffective disorder that prevents adherence to treatment;
* Signs, symptoms or laboratory changes suggestive of acute reinfection by COVID 19;
* Elevated resting heart rate (\>100 beats/min);
* Low or high blood pressure (\<90/60 or \>140/90 mmHg);
* Low blood oxygen saturation (\<95%) at rest, or dyspnea grade 3, 4, or 5 on the Medical Research Council Dyspnea Scale (KOVELIS et al., 2008), or exacerbation of dyspnea on exertion;
* Any condition where exercise is a contraindication such as decompensated heart disease, decompensated diabetes;
* Contraindications to the rehabilitation treatment of post-COVID syndrome recommended by the WHO: presence of heart disease after acute COVID, decrease in blood oxygen saturation after exercise (below 94% or decrease of at least 3% of the baseline saturation), presence of orthostatic hypotension;
* Any photosensitive disease or light sensitivity condition;
* Loss of follow-up at the follow-up clinical outpatient clinic, despite maintaining use of PBM according to the study protocol;
* Pregnancy;
* Any adverse effect on the previous use of PBM.

Primary outcomes:
measure: Brazilian version of the SF 36 Quality of Life Scale
timeFrame: pre-treatment and post-treatment moment (after 04 weeks of treatment)
measure: Nutritional assessment
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
measure: Salivary ph, Stimulated salivary flow and unstimulated salivary flow
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
measure: Oral Health Impact Profile (OHIP-14)
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
measure: Xerostomia Inventory XI
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
measure: Functional Independence Measure (FIM)
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
measure: Post-Covid-19 Functional Status Scale
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
measure: The World Health Organization Disability Assessment Schedule (WHODAS 2.0)
timeFrame: pre-treatment and post-treatment (after 04 weeks of treatment)
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Universidade Nove de Julho / Post-Graduate program Biophotonics Applied to Health Sciences
Study officials:
affiliation: University of Nove de Julho
name: Rebeca B Cecatto, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chowdhury F, Grigoriadou S, Bombardieri M. Severity of COVID-19 infection in primary Sjogren's syndrome and the emerging evidence of COVID-19-induced xerostomia. Clin Exp Rheumatol. 2021 Nov-Dec;39 Suppl 133(6):215-222. doi: 10.55563/clinexprheumatol/k7x3ta. Epub 2021 Dec 16.
citation: Verma H, Shah J, Akhilesh K, Shukla B. Patients' perspective about speech, swallowing and hearing status post-SARS-CoV-2 (COVID-19) recovery: E-survey. Eur Arch Otorhinolaryngol. 2022 May;279(5):2523-2532. doi: 10.1007/s00405-021-07217-2. Epub 2022 Jan 21.